Severe immune-related autoimmune hemolytic anemia induced by pembrolizumab: a case report with novel immunosuppressive strategy

• by Qin Ye, Meng Li, Ping Zhou, Shan Huang, Ke Xie

• May 8, 2026

A RACE AGAINST TIME AND DISEASE

“We’ve made great strides treating melanoma at Fox Chase and have built one of the most comprehensive multidisciplinary teams in the region—an expertise recognized nationally and internationally,” says Jeffrey M. Farma, MD, FACS, Chair and Professor, Department of Surgery, Fox Chase Cancer Center. “I’m thrilled to bring TIL (tumor-infiltrating lymphocyte) therapy to our metastatic melanoma patients who are not responding to their first-line treatment—a cellular therapy which requires critical timing and a highly specialized multidisciplinary team to deliver it.”

• by

• September 15, 2025

• 4 min

Optimizing treatment of brain metastases in an era of novel systemic treatments: a single center consecutive series

• by P. van Schie, B. L. T. Rijksen, M. Bot, T. Wiersma, L. G. Merckel, D. Brandsma, A. Compter, P. C. de Witt Hamer, R. Post, G. R. Borst

• June 2, 2023

Management of liver metastases from uveal melanoma

• by Anne Huibers, Andrew Wong, Mark Burgmans, Lars Ny, Gustav Stålhammar, Ellen Kapiteijn, Jonathan S Zager, Roger Olofsson Bagge

• August 5, 2025